首页> 外文期刊>Materials science & engineering, C. Materials for Biogical applications >Red fluorescent ZnO nanoparticle grafted with polyglycerol and conjugated RGD peptide as drug delivery vehicles for efficient target cancer therapy
【24h】

Red fluorescent ZnO nanoparticle grafted with polyglycerol and conjugated RGD peptide as drug delivery vehicles for efficient target cancer therapy

机译:用聚甘油和缀合的RGD肽接枝作为药物递送载体的红色荧光ZnO纳米粒子,用于有效靶向癌症治疗

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In the field of modem nanomedicine, ZnO nanoparticles were considered as an emerging candidate for drug delivery because of their inherent biocompatibility and stability. However, the poor dispersibility in a physiological medium obstructed their clinic applications. In this paper, the red fluorescence ZnO nanoparticles were synthesized, using a facile chemical method of polyol in boiling trimethylene glycol (TREG) with zinc acetate. The as-synthesized ZnO nanoparticles were first time grafted with PG layer through ring-opening polymerization of glycidol (ZnO-PG). As calculated from the TGA data, the weight ratio of the grafted PG was about 68 wt%. Then, the ZnO-PG engineered to conjugate with arginine-glycine-aspartate (RGD) peptide by stepwise organic reactions. Finally, anticancer drugs Doxorubicin hydrochloride (DOX) was immobilized on ZnO-PG-RGD (approximately 21.8 +/- 0.9 nm) to form ZnO-PG-RGD/DOX. The drug release percentage reaches 70.6% within 48 h under pH 5.2, which was more than 3-fold higher than that pH 7.4. The properties of ZnO nanoparticles and its derivatives were detected by power XRD, TEM, EDS, FTIR, TGA, DLS, Zeta potential and UV. The grafted PG layer not only largely enhanced the dispersibility, but also inhibited ZnO nanoparticles from the uptake by U87MG and Hela cells. In contrast, ZnO-PG-RGD was selectively taken up by U87MG, not Hela cells, demonstrating an obvious targeting property. When ZnO-PG-RGD/DOX was used, U87MG cells showed specificity damaged compared with Hela cells. Thus, functionalized ZnO nanoparticle was a promising nanomaterial in cancer theranostics.
机译:在调制解调器纳米胺的领域中,由于其固有的生物相容性和稳定性,将ZnO纳米颗粒被认为是用于药物递送的新出现候选者。然而,生理介质中的可差性差阻碍了其临床应用。在本文中,合成了红荧光ZnO纳米颗粒,在沸腾的三甲基乙二醇(Treg)中使用含有锌氢化锌的化学方法。首先通过缩水甘油(ZnO-PG)的开环聚合,首先用PG层接枝的作为合成的ZnO纳米颗粒。如从TGA数据计算的,接枝PG的重量比为约68wt%。然后,通过逐步有机反应设计与精氨酸 - 甘氨酸 - 天冬氨酸(RGD)肽的ZnO-PG通过逐步有机反应缀合。最后,将抗癌药物盐酸盐素(DOX)固定在ZnO-PG-RGD(约21.8 +/- 0.9nm)上以形成ZnO-PG-RGD / dox。在pH 5.2下,药物释放率在48小时内达到70.6%,比pH 7.4高出3倍。通过功率XRD,TEM,EDS,FTIR,TGA,DLS,Zeta电位和UV​​检测ZnO纳米粒子及其衍生物的性质。接枝的PG层不仅在很大程度上增强了分散性,而且还抑制了U87MG和HeLa细胞的摄取中抑制ZnO纳米颗粒。相反,通过U87Mg,而不是HeLa细胞选择性地吸收ZnO-PG-RGD,证明了一种明显的靶向性。使用ZnO-PG-RGD / DOX时,与HELA细胞相比,U87mg细胞显示出特异性损坏。因此,官能化ZnO纳米粒子是癌症治疗癌中有希望的纳米材料。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号